Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

International variation in prostate cancer incidence and mortality rates.

Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F.

Eur Urol. 2012 Jun;61(6):1079-92. doi: 10.1016/j.eururo.2012.02.054. Epub 2012 Mar 8.

PMID:
22424666
2.

Cancer burden in Africa and opportunities for prevention.

Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, Parkin DM.

Cancer. 2012 Sep 15;118(18):4372-84. doi: 10.1002/cncr.27410. Epub 2012 Jan 17. Review.

3.

International trends in liver cancer incidence rates.

Center MM, Jemal A.

Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2362-8. doi: 10.1158/1055-9965.EPI-11-0643. Epub 2011 Sep 15.

4.

Changes in smoking prevalence among U.S. adults by state and region: Estimates from the Tobacco Use Supplement to the Current Population Survey, 1992-2007.

Jemal A, Thun M, Yu XQ, Hartman AM, Cokkinides V, Center MM, Ross H, Ward EM.

BMC Public Health. 2011 Jun 29;11:512. doi: 10.1186/1471-2458-11-512.

5.

Global cancer statistics.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.

CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.

6.

Global patterns of cancer incidence and mortality rates and trends.

Jemal A, Center MM, DeSantis C, Ward EM.

Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907. doi: 10.1158/1055-9965.EPI-10-0437. Epub 2010 Jul 20. Review.

7.

The convergence of lung cancer rates between blacks and whites under the age of 40, United States.

Jemal A, Center MM, Ward E.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3349-52. doi: 10.1158/1055-9965.EPI-09-0740.

8.

The global burden of cancer: priorities for prevention.

Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM.

Carcinogenesis. 2010 Jan;31(1):100-10. doi: 10.1093/carcin/bgp263. Epub 2009 Nov 24.

9.

Worldwide variations in colorectal cancer.

Center MM, Jemal A, Smith RA, Ward E.

CA Cancer J Clin. 2009 Nov-Dec;59(6):366-78. doi: 10.3322/caac.20038. Review.

10.

International trends in colorectal cancer incidence rates.

Center MM, Jemal A, Ward E.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1688-94. doi: 10.1158/1055-9965.EPI-09-0090.

11.

Cancer occurrence.

Jemal A, Center MM, Ward E, Thun MJ.

Methods Mol Biol. 2009;471:3-29. doi: 10.1007/978-1-59745-416-2_1.

PMID:
19109772
12.

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control.

Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK.

J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94. doi: 10.1093/jnci/djn389. Epub 2008 Nov 25.

14.
15.

Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells.

Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, Roux F.

J Neurochem. 1998 Aug;71(2):705-15.

16.

Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42.

Moran E, Cleary I, Larkin AM, Amhlaoibh RN, Masterson A, Scheper RJ, Izquierdo MA, Center M, O'Sullivan F, Clynes M.

Eur J Cancer. 1997 Apr;33(4):652-60.

PMID:
9274450
17.
18.

ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump.

Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, Keppler D.

Biochem J. 1996 Mar 1;314 ( Pt 2):433-7.

19.
21.

Phosphorylation of the multidrug resistance associated protein gene encoded protein P190.

Ma L, Krishnamachary N, Center MS.

Biochemistry. 1995 Mar 14;34(10):3338-43.

PMID:
7880829
22.

ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein.

Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D.

Cancer Res. 1994 Sep 15;54(18):4833-6.

24.

Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin.

Krishnamachary N, Ma L, Zheng L, Safa AR, Center MS.

Oncol Res. 1994;6(3):119-27.

PMID:
7994083
25.
27.
28.

Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.

Rahman A, Husain SR, Siddiqui J, Verma M, Agresti M, Center M, Safa AR, Glazer RI.

J Natl Cancer Inst. 1992 Dec 16;84(24):1909-15.

PMID:
1361008
30.
31.

The gene encoding vacuolar H(+)-ATPase subunit C is overexpressed in multidrug-resistant HL60 cells.

Ma L, Center MS.

Biochem Biophys Res Commun. 1992 Jan 31;182(2):675-81.

PMID:
1370888
32.
34.

Cloning and sequencing a cDNA encoding human ribosomal protein S25.

Li ML, Latoud C, Center MS.

Gene. 1991 Nov 15;107(2):329-33.

PMID:
1748303
35.

Involvement of vacuolar H(+)-adenosine triphosphatase activity in multidrug resistance in HL60 cells.

Marquardt D, Center MS.

J Natl Cancer Inst. 1991 Aug 7;83(15):1098-102.

PMID:
1831509
36.

Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine.

Ma LD, Marquardt D, Takemoto L, Center MS.

J Biol Chem. 1991 Mar 25;266(9):5593-9.

37.
39.

Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression.

McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS.

Biochem Pharmacol. 1989 Oct 15;38(20):3611-9.

PMID:
2573357
40.

Multiple mechanisms of adriamycin resistance in the human leukemia cell line CCRF-CEM.

McGrath T, Marquardt D, Center MS.

Biochem Pharmacol. 1989 Feb 1;38(3):497-501.

PMID:
2563654
43.

Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein.

McGrath T, Center MS.

Biochem Biophys Res Commun. 1987 Jun 30;145(3):1171-6.

PMID:
2886122
47.
49.
50.

Supplemental Content

Loading ...
Support Center